17 October 2017 - We marked an important milestone in the U.S. generic drug program on 1 October 2017 – the start of the first reauthorisation of the Generic Drug User Fee Amendments. 

These fees from industry provide FDA with vital funding that advances the Agency’s regulatory work to review and approve applications for generic drugs.

This wasn’t just a milestone for FDA – it was a victory for public health. Increasing consumer access to safe, high-quality, and affordable generic drugs is a top priority at FDA. Generic drugs often cost a fraction of the price of the brand-name version and almost 9 out of 10 prescriptions are filled using generic drugs. During the past decade, generic medicines have saved the American health care system almost $1.7 trillion.

Read FDA blog